MERS-CoV: Understanding the Latest Human Coronavirus Threat

Viruses. 2018 Feb 24;10(2):93. doi: 10.3390/v10020093.

Abstract

Human coronaviruses cause both upper and lower respiratory tract infections in humans. In 2012, a sixth human coronavirus (hCoV) was isolated from a patient presenting with severe respiratory illness. The 60-year-old man died as a result of renal and respiratory failure after admission to a hospital in Jeddah, Saudi Arabia. The aetiological agent was eventually identified as a coronavirus and designated Middle East respiratory syndrome coronavirus (MERS-CoV). MERS-CoV has now been reported in more than 27 countries across the Middle East, Europe, North Africa and Asia. As of July 2017, 2040 MERS-CoV laboratory confirmed cases, resulting in 712 deaths, were reported globally, with a majority of these cases from the Arabian Peninsula. This review summarises the current understanding of MERS-CoV, with special reference to the (i) genome structure; (ii) clinical features; (iii) diagnosis of infection; and (iv) treatment and vaccine development.

Keywords: MERS-CoV; clinical features; human coronavirus; lower respiratory tract infections; respiratory viruses; upper respiratory tract infections.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antiviral Agents / therapeutic use
  • Coronavirus Infections / diagnosis*
  • Coronavirus Infections / prevention & control
  • Coronavirus Infections / therapy
  • Coronavirus Infections / transmission
  • Disease Models, Animal
  • Genome, Viral
  • Humans
  • Middle East Respiratory Syndrome Coronavirus / genetics
  • Middle East Respiratory Syndrome Coronavirus / immunology
  • Middle East Respiratory Syndrome Coronavirus / pathogenicity*
  • Respiratory Tract Infections / diagnosis*
  • Respiratory Tract Infections / virology
  • Vaccines / isolation & purification
  • Viral Proteins

Substances

  • Antiviral Agents
  • Vaccines
  • Viral Proteins